Application of a screening method for fentanyl and its analogues using UHPLC-QTOF-MS with data-independent acquisition (DIA) in MSE mode and retrospective analysis of authentic forensic blood samples

2017 ◽  
Vol 10 (4) ◽  
pp. 651-662 ◽  
Author(s):  
Carolina Noble ◽  
Petur Weihe Dalsgaard ◽  
Sys Stybe Johansen ◽  
Kristian Linnet
Keyword(s):  
Retrospective Analysis ◽  
Screening Method ◽  
Blood Samples ◽  
Data Independent Acquisition

The study of gases markers to diagnosisi the pathology of the uterine body

10.12737/5027 ◽  
2014 ◽  
Vol 8 (1) ◽  
pp. 1-9
Author(s):  
Кучменко ◽  
T. Kuchmenko ◽  
Битюкова ◽  
T. Bityukova ◽  
Ковалева ◽  
...  
Keyword(s):  
Screening Method ◽  
Digital Signal ◽  
Cancer Diagnostics ◽  
Blood Samples ◽  
Three Samples ◽  
Disease Diagnostics ◽  
Preliminary Preparation ◽  
Three Stages ◽  
Weighing Method ◽  
Uterine Body

At present there is no screening method for early uterus body cancer diagnostics and its monitoring. This research offers the new developed and standardized technique of gases markers by means of piezoquartz micro weighing method. This study includes three stages: preliminary preparation of blood samples by applying them on piezoresistors of modifiers-sorbents with high selectivity to main gases indicating pathogenic processes; conversion of sensors into digital signal; data analysis and processing exploiting the software package. The study demonstrates the opportunities and prospects of the developed approach to seach of potential gases-markers of endometrium cancer. Forty eight blood samples have been screened, including eleven control samples and twenty three samples with benign uterus body pathology: leiomyoma, uterus body endometriosis; fourteen samples with endometrium cancer. It has been found that by geometry peculiarities, the size of visual print and sorption efficiency parameters blood samples can be reliably ranked into groups according to their diagnostic specification. The study has resulted in detection of gases-markers which can be prospectively used for uterus body disease diagnostics.

Non-Aqueous CE Screening Method for 14 Psychotropic Drugs in Whole Blood Samples

2007 ◽  
Vol 65 (5-6) ◽  
pp. 313-317 ◽  
Author(s):  
K. Madej ◽  
A. Marczyk ◽  
M. Woźniakiewicz
Keyword(s):  
Psychotropic Drugs ◽  
Whole Blood ◽  
Screening Method ◽  
Blood Samples ◽  
Whole Blood Samples

scholarly journals MTT FORMAZAN REPLACED WST-8 AS A BETTER SIMPLE SCREENING METHOD FOR DETECTION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY

2019 ◽  
Vol 7 (6) ◽  
pp. 161
Author(s):  
Indah Tantular
Keyword(s):  
Screening Method ◽  
Residual Activity ◽  
Rapid Screening ◽  
Blood Samples ◽  
Naked Eye ◽  
Rapid Screening Test ◽  
Hydrogen Carrier ◽  
Purple Color ◽  
Glucose 6 Phosphate Dehydrogenase ◽  
Simple Screening

We have previously developed the WST-8 method as a simple and rapid screening test for detection of glucose-6-phosphate dehydrogenase (G6PD) deficiency accomplished by the naked eye. However, it was little difficult to distinguish between faint orange colors developed by heterozygous females and pink colors of normal hemolyzed blood, since both have similar tones. To solve this problem, we established a new and simple screening method that utilizes another formazan substrate, MTT (3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyl-2H tetrazolium bromide) in combination with a hydrogen carrier, 1-methoxy phenazine methosulfate. MTT formazan exhibits a purple color, thus allowing for the ability to easily distinguish the pink colors of hemolyzed blood. However, MTT has been reported to react with hemoglobin non-specifically and to interfere with the interpretation of the color reaction. In our examinations by mixing MTT with hemolyzed blood, we found that the non-specific reaction was very slow, and that the addition of a small amount of blood (5~10 μl) into a reaction mixture (800 μl) did not interfere with the reaction of G6PD activity. In this new MTT method, a strong purple color was generated in normal blood samples at 20~30 min after incubation, which could be distinguished by the naked eye from G6PD-deficient blood samples with less than 50% residual activity. In addition, quantitative measurement using a spectrophotometer was also possible despite the fact that MTT formazan is water-insoluble.

scholarly journals Role of Point-of-Care Device in Improving Sickle Cell Newborn Screening Feasibility in Haiti

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 3670-3670
Author(s):  
Ofelia A. Alvarez ◽  
Tally Hustace ◽  
Mimose Voltaire ◽  
Rodrigueson Rizil ◽  
Ulrick Liberus ◽  
...  
Keyword(s):  
Newborn Screening ◽  
Sickle Cell ◽  
Conflicts Of Interest ◽  
Point Of Care ◽  
Screening Method ◽  
Beta Thalassemia ◽  
Blood Samples ◽  
Confirmatory Testing ◽  
Hemoglobin C

Abstract Introduction: Until 2017, hemoglobinopathy newborn screening (NBS) was not offered in Haiti, a country with about 243,000 births per year. Sickle SCAN is a rapid point-of-care (POC) with lateral flow immunoassay technology, but its role in NBS is unknown. Recently, over 100 dried blood samples from newborns were tested [Nguyen-Khoa T, Ann Biol Clin (Paris), 2018] in France with accurate results. Objective: This work had the objective to be proof-of-concept that a hospital-based NBS program is feasible in Haiti and to examine the role of Sickle SCAN in NBS in a larger sample size. Methods: The Ethics Committee at the Universitaire Justinien Hospital (HUJ) and the Institutional Review Board at the University of Miami approved this study. We formed a Haitian team composed of a pediatrician on staff (RSF), two dedicated NBS nurses, a program coordinator (MV), two community health workers, a laboratory technician (RR), and a data manager (UL). We acquired isoelectric focusing equipment (IEF) and performed NBS from dried blood samples only for the first three months while the technician gained proficiency. Thereafter, we have performed dual screening method with the POC device Sickle SCAN and IEF. Confirmatory testing was obtained with both methods. Data were entered into RED Cap. Results: Beginning in August 2017 until present (June 2018), we have screened 1,800 newborns, of which 10.5% have sickle cell trait, 3.3% have hemoglobin C trait, 0.78% have hemoglobin SS, 0.27% have hemoglobin SC and one child has been confirmed to have sickle beta thalassemia plus. Currently, there are 15 children followed at HUJ, for a SCD incidence of 0.83% (8 SS, 6 SC and 1 S-beta thalassemia+). Before the POC screening was implemented two infants have already died when the mothers were contacted (one who screened positive for FS and another for FC). The POC allows for immediate referral and penicillin prophylaxis for at-risk children until the cases are confirmed. Systemic barriers encountered are the electrical outages and intense heat which impacted IEF performance, material procurement (laboratory materials, NBS materials, oral penicillin) which are dependent of shipments from outside of Haiti. Conclusions: A hospital-based NBS Program is feasible. SCD is highly prevalent with an incidence of 0.83% among newborns in the population studied. Based on this incidence, we estimate that every year around 2,000 children will be born with sickle cell disease in Haiti. The point-of-care device enhanced the screening program by obtaining immediate screening results and maximizing family notification for confirmatory testing. Disclosures No relevant conflicts of interest to declare.

scholarly journals A rapid and efficient screening system for neutralizing antibodies and its application for SARS-CoV-2

2020 ◽  
Author(s):  
Xiaojian Han ◽  
Yingming Wang ◽  
Shenglong Li ◽  
Chao Hu ◽  
Tingting Li ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Neutralizing Antibodies ◽  
Inhibitory Concentration ◽  
Screening Method ◽  
Emerging Infectious Diseases ◽  
Receptor Binding Domain ◽  
Screening System ◽  
Blood Samples ◽  
Therapeutic Value ◽  
Efficient Screening

Abstract After the epidemic of COVID-19, neutralizing antibodies (NAbs) against SARS-CoV-2 has been developed for the preventative and therapeutic purposes. However, few methodologies are reported in detail on how to rapidly and efficiently generate NAbs of interest. Here, we present a strategically optimized screening method for NAbs, which has enabled us to obtain SARS-CoV-2 receptor-binding domain (RBD) specific monoclonal Abs within 4 days, followed by additional 2 days to evaluate their neutralizing activities. Using this method, we obtained 198 specific Abs against SARS-CoV-2 RBD from the blood samples of COVID-19 convalescent patients, and 96 of them showed neutralizing activity. At least 20% of these NAbs exhibited high neutralizing potency. The top 2 NAbs showed the half-maximal inhibitory concentration (IC50) to block authentic SARS-CoV-2 at 9.88 and 11.13 ng/ml, respectively. Altogether, our study provides a fundamental methodology for discovering NAbs with potential preventative and therapeutic value for emerging infectious diseases.

scholarly journals Evaluation of Automatic Blood Analyzer as Screening Method in Fetomaternal Hemorrhage

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Marcella R. Cardoso ◽  
Caroline N. de Souza-Araújo ◽  
Maria Cecília R. Talarico ◽  
Juliana Heinrich-Mouçouçah ◽  
Fernando Guimarães ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Blood Cells ◽  
Area Under Curve ◽  
Critical Level ◽  
Screening Method ◽  
Fetal Hemoglobin ◽  
Fetal Blood ◽  
Blood Samples ◽  
Fetomaternal Hemorrhage ◽  
Performance Area

Screening of fetomaternal hemorrhage (FMH) is essential in management of fetomaternal antigen incompatibilities of blood. The objective in this study was to evaluate the ability of automatic blood analyzer (ABA) to screen FMH, also comparing this method with flow cytometry (FCM). The contents of fetal red blood cells and fetal hemoglobin were evaluated by FCM and ABA, respectively, using both blood samples of male adults laced with umbilical cord blood diluted at 1/10, 1/100, 1/1,000, and 1/10,000, or blood from puerperal women collected within 48 hours following delivery. FCM had better performance (area under curve, AUC = 0.8723) than ABA (AUC = 0.6569) in detecting fetal blood laced with blood from male adults. At a critical level of 0.5%, ABA indicated that 27.5% of puerperal women would have FMH while FCM did not detect FMH. Our results showed that ABA overestimates FMH and disagrees with FCM on indicating puerperal women with FMH. ABA is inadequate for being used to screen for or to measure FMH.

scholarly journals Performance of cell-free DNA sequencing-based non-invasive prenatal testing: experience on 36,456 singleton and multiple pregnancies

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Marco La Verde ◽  
Luigia De Falco ◽  
Annalaura Torella ◽  
Giovanni Savarese ◽  
Pasquale Savarese ◽  
...  
Keyword(s):  
Dna Sequencing ◽  
Retrospective Analysis ◽  
False Negative ◽  
Screening Method ◽  
Prenatal Testing ◽  
Maternal Blood ◽  
Cell Free Dna ◽  
Detection Rates ◽  
Non Invasive ◽  
Free Dna

Abstract Background This paper describes the clinical practice and performance of cell-free DNA sequencing-based non-invasive prenatal testing (NIPT) as a screening method for fetal trisomy 21, 18, and 13 (T21, T18, and T13) and sex chromosome aneuploidies (SCA) in a general Italian pregnancy population. Methods The AMES-accredited laboratory offers NIPT in maternal blood as a screening test for fetal T21, T18, T13 and SCA. Samples were sequenced on a NextSeq 550 (Illumina) using the VeriSeq NIPT Solution v1 assay. Results A retrospective analysis was performed on 36,456 consecutive maternal blood samples, including 35,650 singleton pregnancies, 800 twin pregnancies, and 6 triplet pregnancies. Samples were tested between April 2017 and September 2019. The cohort included 46% elevated-risk and 54% low-risk patients. A result indicative of a classic trisomy was found in 356 (1%) of singleton or twin samples: 254 T21, 69 T18, and 33 T13. In addition, 145 results (0.4%) were indicative of a SCA. Of the combined 501 screen-positive cases, 484 had confirmatory diagnostic testing. NIPT results were confirmed in 99.2% (247/249) of T21 cases, 91.2% (62/68) of T18 cases, 84.4% (27/32) of T13 cases, and 86.7% (117/135) of SCA cases. In the 35,955 cases reported as unaffected by a classic trisomy or SCA, no false negative cases were reported. Assuming that false negative results would be reported, the sensitivity of NIPT was 100.00% for T21 (95% Cl 98.47–100.0), T18 (95% Cl 94.17–100.0), and T13 (95% Cl 87.54–100.0). The specificities were 99.99% (95% Cl 99.98–100.0), 99.98% (95% Cl 99.96–100.0), 99.99% (95% Cl 99.97–100.0), and 99.95% (95% Cl 99.92–99.97) for T21, T18, T13, and SCA, respectively. Conclusion This retrospective analysis of a large cohort of consecutive patients who had whole-genome sequencing-based NIPT for classic trisomies and SCA shows excellent detection rates and low false positive rates.

scholarly journals Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology

2021 ◽  
Author(s):  
Lukas Krasny ◽  
Paul H. Huang
Keyword(s):  
Mass Spectrometry ◽  
Retrospective Analysis ◽  
Next Generation ◽  
Data Independent Acquisition ◽  
Tissue Specimens

Data-independent acquisition mass spectrometry (DIA-MS) is a next generation proteomic methodology that generates permanent digital proteome maps offering highly reproducible retrospective analysis of cellular and tissue specimens.

Sign in / Sign up

Export Citation Format

Share Document